Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers July 23, 2014
Pharmacy Choice - News - Generic Drugs - July 23, 2014

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 28     Next >>     Go To Page:

7/23/14 - Indoco Remedies gets USFDA nod for Goa's sterile and solid dosage facilities [Global Data Point]
"The approval will now facilitate the generic approvals in the US market and subsequent product launches there. Without doubt, it will also boost the high-margin revenues of Indoco from the remunerative market of US and placing Indoco in the elite league with other International and Indian pharmaceutical companies, "said Suresh G. Kare, Chairman, I
7/23/14 - Mylan Wins Motion For Temporary Restraining Order Against Apotex Generic Paxil
CANONSBURG- Generic drugmaker Mylan Inc. said the U.S. District Court for the District of New Jersey granted its motion for a temporary restraining order against Apotex Inc. and Apotex Corporation in litigation pertaing to Paroxetine CR, the authorized generic of GlaxoSmithKline's Paxil CR. Mylan previously obtained an order enjoining GlaxoSmithKli
7/23/14 - Researchers at University of Cairo Have Reported New Data on Recombinant Granulocyte Colony Stimulating Factor (Chromatographic and electrophoretic...
According to news reporting from Cairo, Egypt, by NewsRx journalists, research stated, "An orthogonal testing protocol was developed and validated to assess the quality of Filgrastim biosimilars. SEC and CIEF were used under non-denaturing conditions to reveal high molecular weight and charged impurities, respectively. SEC was carried out over a mo
7/22/14 - Dora Akunyili - The Nigerian Public Servant Who Took on the Fake Drugs Trade
By Pete Kingsley, University of Edinburgh. With the death of Nigeria's Dora Akunyili, a passionate campaigner against falsified and substandard medicines, the fight against fake drugs in Africa just got more difficult. Akunyili was director-general of the country's National Agency for Food and Drug Administration and Control from 2001 to 2009. Duri
7/22/14 - Strides buys generics unit of Bafna Pharma [DNA : Daily News & Analysis (India)]
Mumbai: Bangalore- based Strides Arcolab, on Monday, said it has entered into an agreement with Chennai- based Bafna Pharmaceuticals to acquire majority stake of its branded generic business for a cash consideration of Rs 48.1 crore. It is the 8th largest in oral haematinic segment in India with 8 SKU's in oral and liquid forms with an annual reven
Strides Arcolab Ltd has acquired a stake of 74 percent in the branded generics business of Bafna Pharmaceuticals Ltd for Rs48.1 crore. The company will transfer the business, Raricap, to a special purpose vehicle. Bafna has 400 employees in the generics business and had reported revenue of Rs24.6 crore for 2013-2014. Strides intends to use the gene
7/22/14 - UAE pharma sector in good health [National, The (United Arab Emirates)]
In what was a first for the region in the pharmaceutical sector, Dubai Investments sold a majority stake in its subsidiary Globalpharma to the French multinational Sanofi last month. The move helped DI net Dh385 million, or a 26 per cent in internal rate of return for over 10 years, as it expects to benefit from Sanofi's generics portfolio and pipe
7/21/14 - Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ (lorcaserin HCl) in Israel
Under the agreement, Arena granted Abic the rights to market and distribute BELVIQ in Israel for weight loss or weight management in obese and overweight patients, subject to regulatory approval by the State of Israel Ministry of Health. Abic is responsible for regulatory approval and, ultimately, marketing and distribution of BELVIQ in Israel, inc
7/21/14 - Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020
A new report by Allied Market Research titled, "Global biosimilars/follow-on-biologics market- Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013- 2020", suggests that the global biosimilars market would reach $35 billion by 2020 from the estimated $1.3 billion
7/21/14 - Mylan Launches Generic Micardis Tablets
Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, had U.S. sales of approximately $259.2 million for the 12 months ending March 31, 2014, according to IMS Health. Currently, Mylan has 305 ANDAs pending FDA approval representing $107.2 billion in annual brand sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file
7/21/14 - Par Pharmaceutical Begins Shipment of Fluphenazine Decanoate Injection, USP
By a News Reporter-Staff News Editor at Pharma Business Week Par Pharmaceutical Companies, Inc. announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fluphenazine decanoate injection, USP 25 mg/mL. Fluphenazine decanoate injection is a long-acting parenteral antipsych
7/21/14 - Perrigo Announces FDA Final Approval For The Store Brand Equivalent To Advil Congestion Relief Tablets, 200 mg/10 mg
By a News Reporter-Staff News Editor at Pharma Business Week Perrigo Company announced that it was the first to receive final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for ibuprofen and phenylephrine hydrochloride tablets, 200 mg/10 mg, the store brand equivalent to Advil Congestion Relief Tablet
7/21/14 - Research and Markets: India Pharmaceutical Market 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMs), Biosimilars, Generics & Vaccines
Research and Markets has announced the addition of the "Pharmaceutical Market India 2014-2020, Formulations, Active Pharmaceutical Ingredients, Contract Research and Manufacturing Services, Biosimilars, Generics& Vaccines" report to their offering. PHARMACEUTICAL MARKET INDIA 2014-2020, Formulations, Active Pharmaceutical Ingredients, Contract...
7/21/14 - Teva Completes Acquisition of Labrys: Opens Door to a Strong and Novel Migraine Prevention and Treatment Franchise within its CNS Portfolio
Teva Pharmaceutical Industries Ltd. today announced the successful completion of the acquisition of Labrys. Teva s acquisition of LBR-101 complements the recent acquisition of ZECUITY , a novel iontophoretic patch that delivers sumatriptan via the skin for the acute treatment of migraine, and positions Teva to compete for leadership in the tre
7/20/14 - FDA chief tells chemists to give generic drugs [Pune] [Times of India]
PUNE: The Food and Drug Administration will issue prescription guidelines to doctors through chemists to facilitate distribution of generic medicines among poor, said FDA commissioner Mahesh Zagade. There are three lakh doctors in the state and only 120 drug inspectors with the FDA. The FDA commissioner also said that wholesalers' stocks will be in
7/19/14 - Actavis Files ANDA with FDA to Market Generic Version of Acorda Therapeutics' Ampyra [Professional Services Close - Up]
Actavis said that Acorda Therapeutics filed suit against the Company on July 7, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of certain U.S. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval
Medicine Patent Pool has signed an agreement with seven pharmaceutical companies to produce generic versions of anti-AIDS medicines. Cipla, Emcure, Aurobindo, Micro Labs and Mylan of India are among the companies to produce the drugs. The companies will manufacture generic versions of atazanavir and dolutegravir.
7/18/14 - Teva to Report Second Quarter 2014 Financial Results on July 31, 2014
Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its second quarter 2014 results and overall business environment. A live webcast of the call will also be available on Teva's website at: Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product port
7/17/14 - AbbVie Inc., et al.; Withdrawal of Approval of Abbreviated New Drug Applications for Prescription Pain Medications Containing More Than 325...
SUPPLEMENTARY INFORMATION: In the Federal Register of January 14, 2011, FDA announced its plans to reduce the maximum dosage unit strength of acetaminophen in prescription drug products. Accordingly, we asked product sponsors to limit the maximum amount of acetaminophen per dosage unit to 325 mg and, for those products containing more than 325 mg o
7/17/14 - ABPI and BIA Jointly Launch New Communication Materials to Enhance Understanding of Biosimilar Medicines
The Association of the British Pharmaceutical Industry issued the following news release:. The Association of the British Pharmaceutical Industry and the Bioindustry Association have jointly developed materials on biological medicines, including biosimilar medicines, to enhance prescribers' and other stakeholders' understanding of these medicines..
7/17/14 - EDITORIAL: Corporate tax inversions: Prevent more Mylans [The Pittsburgh Tribune-Review :: ]
In what's known as a "corporate tax inversion," generic drug giant Mylan Inc. is acquiring, for $5.3 billion in stock, Abbott Laboratories' overseas generic business based in the Netherlands and reorganizing as a corporation based there. Carl Levin, D- Mich., has proposed a two-year moratorium on tax inversion deals. Sander M. Levin of Michigan,
7/17/14 - Issa, Jordan, Woodall Probe FDA's Giveaway to Trial Lawyers
"FDA developed the proposed rule to ensure manufacturers of generic drugs would face liability, and resulting litigation, by establishing a process for generic drug manufacturers to change their label without prior FDA approval," the lawmakers wrote in the letter. The letter notes that on February 15, 2013, the American Association of Justice, form
7/17/14 - Mylan Wins Motion To Enjoin GlaxoSmithKline From Providing Paroxetine CR Yo Apotex; Apotex Can No Longer Supply Authorized Generic Product
Mylan Inc. today announced that the U.S. District Court for the District of New Jersey granted its motion for a permanent injunction against GlaxoSmithKline in relation to Paroxetine CR, the generic version of GSK's Paxil CR. Mylan had previously been awarded damages in the amount of $106,700,000 by the District Court after a favorable jury verd
7/17/14 - PharmaBoardroom Releases New Poland Pharmaceutical Report
Not only is Poland the largest pharmaceutical market in the Central& Eastern Europe region and the sixth largest in Europe, it is also a hub for production and functional activities. However, Poland has some of the lowest prices of both innovative and generic drugs in Europe. "This is not because Poland cannot afford innovation but rather because
Pharmaceutical company Strides Arcolab of Bangalore has made a series of strategic investments in private pharmaceutical firm Oncobiologicals Inc of New Jersey, which is developing a pipeline of biosimilars and next-generation bio-therapeutics. Oncobiologics was founded by a team of experts from pharmaceutical majors firms such as Pfizer, Merck, El
Articles(s): 1 - 25 of 28     Next >>     Go To Page:

© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Lupus: What You Need to Know
This lesson is supported by:
West Virginia Best Practice Prescribing & Drug Diversion Training
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement